Tazemetostat and Belinostat targeting EZH2 and HDAC simultaneously affect the immunogenicity of GC-DLBC [24].Inhibition of EZH2 by SHR2554 and HDAC by Chidamide demonstrated combinational anti-tumor action in DLBCL as they lessen DNA replication procedures inclusive of ORC1 [25,26]. Here, HDAC9 is linked to neoplasm.